CoTherix, Inc.

Founded as Exhale Therapeutics in February 2000 by Fred Volinsky, Donald Santel, and Gerard Turino, CoTherix was a biopharmaceutical company developing therapies for pulmonary arterial hypertension. The organization secured FDA approval for its inhaled product Ventavis in December 2004 and inlicensed drugs like Fasudil from Asahi Kasei for commercialization rights in the United States and Europe. To fund these treatments, the enterprise raised capital through an October 2004 initial public offering that generated twenty five million two hundred thousand dollars. This was followed by a secondary offering of four million two hundred fifty thousand shares priced at eight dollars and ninety cents each in February 2005. In November 2006, the business agreed to be acquired by Actelion for 420 million dollars in cash, closing in January 2007 at thirteen dollars and fifty cents per share.

# CoTherix, Inc. - High-Level Overview

CoTherix is a biopharmaceutical company focused on developing and commercializing therapeutic products for cardiovascular and cardiopulmonary diseases.[1][3] Founded in 2000, the company operates in the specialty pharmaceutical space, targeting conditions with significant unmet medical needs. CoTherix pursues a licensing and acquisition strategy to build a portfolio of mid- to late-stage clinical products, with particular emphasis on treatments for pulmonary arterial hypertension (PAH) and cardiovascular conditions like stable angina.[4]

The company's business model centers on in-licensing promising therapeutic candidates from other developers and advancing them through clinical development and commercialization in North America and Europe.[4] This approach allows CoTherix to leverage external innovation while building internal capabilities in drug development and direct-to-market sales operations.

# Origin Story

CoTherix was founded in 2000 by Donald Santel, who joined as president and co-founder in February of that year and later became Chief Executive Officer in 2004.[4] The company emerged during a period of growing interest in cardiovascular therapeutics, positioning itself to address a substantial market opportunity—particularly in PAH treatment, where only approximately 30% of patients were diagnosed and receiving treatment as of 2006.[4]

A pivotal moment in the company's early trajectory came in June 2006, when CoTherix in-licensed fasudil from Japan-based Asahi Kasei Pharma.[4] This acquisition represented a strategic expansion of the company's pipeline, bringing an established therapeutic agent into development for oral and inhaled formulations targeting PAH and chronic stable angina in North American and European markets.

# Core Differentiators

• Therapeutic focus: Specialization in cardiovascular and cardiopulmonary diseases, addressing conditions with significant treatment gaps[3][4]
• In-licensing strategy: Ability to identify and acquire mid- to late-stage clinical candidates, reducing early-stage development risk[4]
• Direct commercialization capability: Plans to build internal sales forces for direct market engagement, particularly for PAH treatments[4]
• Geographic expansion: Development rights for North America and Europe, enabling multi-market commercialization[4]

# Role in the Broader Biotech Landscape

CoTherix operates within the specialty pharmaceutical sector, targeting orphan and rare disease markets where patient populations are smaller but treatment options are limited. The company's focus on cardiovascular disease reflects broader industry trends toward addressing chronic conditions with high mortality and morbidity rates. By pursuing an in-licensing model rather than relying solely on internal R&D, CoTherix represents a common biotech strategy of acquiring de-risked assets and applying commercial expertise to bring them to market efficiently.

# Quick Take & Future Outlook

CoTherix's strategy of building a focused portfolio in cardiovascular therapeutics positioned it to capture value in a growing specialty pharma market. The company's ability to identify and advance promising candidates like fasudil, combined with plans for direct commercialization, suggested ambitions to become a meaningful player in cardiopulmonary treatment. Success would depend on advancing pipeline candidates through clinical trials, securing regulatory approvals, and executing effective market entry strategies in competitive therapeutic areas.